Otilonium Bromide: Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄, MW 563.57) is a highly specific antimuscarinic agent for research use only, acting as a competitive inhibitor of acetylcholine receptors (AChR) with a purity of ≥98% (APExBIO). Its exceptional solubility (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol) enables versatile experimental integration. Otilonium Bromide is widely used to dissect cholinergic signaling pathways and model smooth muscle and gastrointestinal motility disorders (contrast: extends on experimental frameworks). It is not approved for diagnostic or therapeutic applications. Proper storage at -20°C and short-term solution use are required for maximal efficacy.

Biological Rationale

Cholinergic signaling regulates critical physiological processes, including smooth muscle contraction, neural transmission, and gastrointestinal motility. Muscarinic acetylcholine receptors (mAChRs) mediate these effects and play central roles in both health and disease states. Aberrant mAChR signaling is implicated in conditions such as irritable bowel syndrome, overactive bladder, and certain neurodegenerative disorders (Vijayan et al., 2021). Antimuscarinic agents are fundamental tools for probing these pathways in controlled research settings. Otilonium Bromide, as a high-affinity mAChR antagonist, enables investigators to selectively inhibit receptor activity and dissect downstream effects. Its use supports the development of mechanistic models and the validation of new therapeutic strategies (contrast: updates utility in disease modeling).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors, blocking endogenous acetylcholine binding. This inhibition reduces intracellular calcium mobilization and suppresses smooth muscle contraction. The compound’s specificity enables selective targeting of mAChR subtypes without significant off-target effects at recommended research concentrations. In vitro, Otilonium Bromide achieves receptor blockade with nanomolar-to-micromolar potency, depending on cell type and assay conditions (contrast: clarifies receptor subtype implications). This mode of action supports studies into cholinergic signaling, synaptic physiology, and pharmacological modulation of gastrointestinal tissues.

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% purity by HPLC, ensuring reproducible experimental results (APExBIO).
• Solubility is quantified as ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at 25°C, pH 7.4 (product specification).
• Inhibition of muscarinic receptor-mediated smooth muscle contraction is observed at 1–10 μM in in vitro tissue bath assays (Vijayan et al., 2021).
• Short-term solution stability (≤7 days at 4°C) is confirmed, with long-term storage recommended at -20°C (manufacturer data).
• Used as a reference antimuscarinic agent in studies modeling gastrointestinal motility disorders (contrast: extends mechanistic context).

Applications, Limits & Misconceptions

Otilonium Bromide is deployed to:

• Inhibit cholinergic neurotransmission in neuroscience and pharmacology research.
• Model gastrointestinal motility disorders and evaluate drug responses in smooth muscle tissues.
• Dissect muscarinic receptor signaling pathways in cellular and tissue-based assays.
• Benchmark antimuscarinic drug potency and selectivity.

It is not intended for clinical, diagnostic, or therapeutic use in humans or animals.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not a pan-cholinergic inhibitor; it does not block nicotinic acetylcholine receptors.
• The compound is not stable in solution beyond one week at 4°C; extended use requires fresh preparation.
• Not appropriate for in vivo studies without validated pharmacokinetic and safety data in the species of interest.
• Misapplication in non-cholinergic pathways will yield misleading results due to receptor selectivity.
• It is not approved for clinical or diagnostic applications.

Workflow Integration & Parameters

To maximize data quality, researchers should:

• Dissolve Otilonium Bromide in DMSO, water, or ethanol at concentrations up to 91 mg/mL (solvent-dependent).
• Aliquot and store at -20°C to maintain compound integrity; avoid repeated freeze-thaw cycles.
• Prepare fresh working solutions for each experiment, using within 7 days when stored at 4°C.
• Apply at validated concentrations (typically 1–10 μM) for selective mAChR inhibition.
• Consult APExBIO’s technical datasheet for detailed handling and compatibility guidance (Otilonium Bromide product page).

Conclusion & Outlook

Otilonium Bromide (APExBIO SKU B1607) stands as a robust, high-purity tool for advanced research on cholinergic signaling and smooth muscle physiology. Its validated specificity, solubility, and stability parameters underpin its widespread adoption in both academic and translational laboratories. Careful adherence to storage, preparation, and application protocols ensures reproducible outcomes. For expanded mechanistic discussion and emerging translational models, see Otilonium Bromide in Translational Neuroscience (this article details updated disease modeling strategies). Ongoing advances in receptor subtype profiling and disease model integration will continue to expand the utility of Otilonium Bromide in preclinical research.